University of Maryland, Baltimore

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Maryland, Baltimore sits in the top decile of US sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count).

560 total trials 103 currently recruiting 332 completed early-phase tilt top decile by trial count

University of Maryland, Baltimore: 560 sponsored US clinical trials, 103 recruiting.

University of Maryland, Baltimore sponsors 560 registered US clinical trials on ClinicalTrials.gov, 103 of them currently recruiting, and 332 completed. 77 of these trials are in Phase 3-4 (later-stage) and 161 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 14 trials.

Top-decile sponsor footprint

University of Maryland, Baltimore ranks in the top decile of sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 42/100

332 of 410 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

560 total, page 7 of 12

TERMINATED NA

Cranial Electric Stimulation to Modify Suicide Risk Factors in Psychiatric Inpatients.

NCT02846740
COMPLETED NA

A Theory-Based Patient Portal eLearning Program for Older Adults With Chronic Illnesses

NCT03242070
COMPLETED NA

Novel Strategies for Innovating Deceased Donor Procurement

NCT03007017
COMPLETED Early Phase 1

PK and DPK of Lidocaine Dermal Products

NCT03145207
COMPLETED Phase 2

Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing

NCT02786498
COMPLETED

Schizophrenia and the Gut Microbiome

NCT02921243
COMPLETED NA

Inpatient Diabetes Mellitus (DM) Management With Continuous Glucose Monitoring Devices, a Pilot Study.

NCT02904512
COMPLETED NA

Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis

NCT02930044
TERMINATED Phase 2

Emergency Preservation and Resuscitation (EPR) for Cardiac Arrest From Trauma

NCT01042015
TERMINATED NA

Loop Drainage: Effectiveness in Treating Cutaneous Abscesses

NCT02697279
COMPLETED NA

Using Spices and Herbs to Increase Vegetable Intake Among Urban High School Students

NCT02908854
COMPLETED NA

Assessing Online Interventions for Men's' Mental Health and Wellbeing

NCT02785471
COMPLETED NA

Treatment of Back Pain Using Transcutaneous Magnetic Stimulation (TCMS)

NCT02421757
COMPLETED Phase 1

Decitabine and Talazoparib in Untreated AML and R/R AML

NCT02878785
TERMINATED Phase 4

Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar

NCT02546492
COMPLETED Phase 3

Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke

NCT02460900
COMPLETED NA

Alpha as a Predictive Biomarker

NCT02796625
TERMINATED NA

Building Blocks for Healthy Preschoolers

NCT03111264
TERMINATED Phase 1

Pharmacogenomics of GLP1 Receptor Agonists

NCT05762744
COMPLETED NA

Prospective, Randomized Controlled Comparison of TERUMO SurFlash Plus Versus BD Insyte Autoguard in an Urban ED

NCT02769442
COMPLETED Early Phase 1

Dose Response of Epinephrine

NCT02692313
COMPLETED Phase 2

Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience

NCT02745535
COMPLETED Phase 4

Treatment of CNS Sarcoidosis With H.P. Acthar Gel

NCT02298491
TERMINATED NA

Enhance Balance and Mobility in People With Type 2 Diabetic Peripheral Neuropathy

NCT02541838
COMPLETED NA

Testing the Implementation of EIT-4-BPSD

NCT03014570
COMPLETED Phase 2

Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women

NCT02683369
TERMINATED

CT for Pulmonary Thromboembolic Disease

NCT02241525
COMPLETED Phase 4

Fentanyl Patch Pharmacokinetics in Healthy Adults

NCT02531971
COMPLETED NA

Direct Gloving Strategy: A Cluster-randomized Trial

NCT03119389
COMPLETED Phase 3

A Different Approach to Preventing Thrombosis

NCT02774265
COMPLETED NA

The Gamma Pod: A Clinical Feasibility Study Device GCC 1202: The Gamma Pod: A Clinical Feasibility Study

NCT02507960
COMPLETED NA

BBOT: Bacterial Burden in Ortho Trauma Procedures

NCT03126448
COMPLETED

Cerebral Autoregulation and Vasospasm in Patients With TBI

NCT02351518
COMPLETED Phase 1

A Safety and Immunogenicity Trial of IHV01

NCT02756208
COMPLETED NA

Sacroiliac (SI) Screws: The Effect of SI Screw Removal on Patient-Reported Pain and Functional Outcomes

NCT02652611
TERMINATED Phase 2

Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults

NCT00890149
COMPLETED NA

Skin Prep to Reduce Postoperative Shoulder Infection

NCT02510144
COMPLETED Phase 2

Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder

NCT02354703
COMPLETED Phase 4

Transdermal Patch CVD 2000: The Effect of Heat on Fentanyl Release From Fentanyl TDSs in Healthy Adults

NCT02486016
COMPLETED Phase 4

BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients

NCT02404168
COMPLETED NA

Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)

NCT02404155
COMPLETED NA

Biomarkers to Measure Treatment Response for Alcohol Dependence

NCT02315885
TERMINATED

Study of Airway Pressure Release Ventilation and Intracranial Pressure in Patients With Severe Traumatic Brain Injury

NCT02507973
COMPLETED

Use of MIBG Scan Images in PVC Ablations

NCT02279030
TERMINATED NA

GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

NCT02095184
COMPLETED NA

Pelvis RCT: Impact of Surgery on Pain in Lateral Compression Type Pelvic Fractures

NCT02625766
COMPLETED NA

Managing Acute Pain in Critically Ill Non-communicative Palliative Care Patients

NCT02127086
TERMINATED Phase 2

Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma

NCT02319304
COMPLETED NA

Robotic Single Port Donor Nephrectomy

NCT01925677
COMPLETED NA

Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia

NCT02069392
← Previous Page 7 of 12 Next →

Phase Distribution

PhaseTrial count
Phase 1 82
Phase 2 79
Phase 3 10
Phase 4 67

Therapeutic Areas

Schizophrenia 14
Schizoaffective Disorder 8
Prostate Cancer 8
HIV 5
Stroke 5
Survivorship 4
Virtual Reality 4
Pain 4
Opioid Use Disorder 4
Neoplasms 3

What is open in the University of Maryland, Baltimore pipeline

103 recruiting of 560 indexed (18% open); 332 completed (59%).

Phase mix: 77 late (III/IV) vs 161 early (I/II) (early-phase heavy).

Top condition: Schizophrenia (14 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Maryland, Baltimore: open-pipeline peers nationwide

Peers matched on 560 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 5%10%15%20%25% Total trials Recruiting share University of Maryland, BaltimoreAmgenMerck Sharp & DohmeVirginia Commonwealth UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Abramson Cancer Center at Penn MedicineHenry Ford Health SystemNew York Institute of TechnologyUniversity of California, San Diego
University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 560 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of Maryland, Baltimore page

560 registered trials is a research-attention snapshot, not an endorsement of University of Maryland, Baltimore or any single study.

  • 103 of University of Maryland, Baltimore's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Schizophrenia is the condition University of Maryland, Baltimore studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Maryland, Baltimore pipeline card: 560 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.